Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alligator Bioscience AB ( (SE:ATORX) ) has issued an announcement.
Alligator Bioscience AB has published a supplement prospectus related to its rights issue, which includes ordinary shares and warrants, approved by the Swedish Financial Supervisory Authority. The rights issue subscription period runs from December 4 to December 18, 2025, with trading in unit rights available until December 15, 2025. This move is part of the company’s strategy to secure additional subscription undertakings and guarantee commitments, potentially strengthening its financial position and supporting its ongoing drug development efforts.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company focused on developing clinical-stage tumor-directed antibody drugs targeting the CD40 receptor. This approach aims to enhance T cell priming and counteract the immunosuppressive tumor microenvironment, offering potential benefits for cancer patients. The company’s lead drug candidate, mitazalimab, is advancing to Phase 3 development, having shown promising results in metastatic pancreatic cancer trials. Alligator Bioscience is listed on Nasdaq Stockholm and is headquartered in Lund, Sweden.
Average Trading Volume: 4,595,953
Technical Sentiment Signal: Sell
Current Market Cap: SEK262.8M
See more insights into ATORX stock on TipRanks’ Stock Analysis page.